Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARDS

Aridis Pharmaceuticals (ARDS)

Aridis Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARDS
DateTimeSourceHeadlineSymbolCompany
06/28/20248:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDSAridis Pharmaceuticals Inc
06/28/20247:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDSAridis Pharmaceuticals Inc
06/28/20247:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDSAridis Pharmaceuticals Inc
06/28/20247:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDSAridis Pharmaceuticals Inc
06/27/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
06/24/20245:58PMGlobeNewswire Inc.Aridis Provides Corporate UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
02/13/20248:02PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
01/16/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
12/15/20234:15PMGlobeNewswire Inc.Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024NASDAQ:ARDSAridis Pharmaceuticals Inc
11/03/20235:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
11/03/20234:15PMGlobeNewswire Inc.Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
11/03/20236:15AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARDSAridis Pharmaceuticals Inc
09/13/20239:47PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARDSAridis Pharmaceuticals Inc
09/07/20234:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
08/25/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
08/04/20234:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
08/04/20234:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
08/03/20234:15PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
08/02/20238:17AMGlobeNewswire Inc.Aridis Pharmaceuticals Announces $2 Million OfferingNASDAQ:ARDSAridis Pharmaceuticals Inc
08/02/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ARDSAridis Pharmaceuticals Inc
07/21/20236:49AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
07/20/20235:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
07/17/20234:05PMGlobeNewswire Inc.Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301NASDAQ:ARDSAridis Pharmaceuticals Inc
07/17/20233:01PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
07/17/20237:36AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
07/12/20238:00AMGlobeNewswire Inc.Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationNASDAQ:ARDSAridis Pharmaceuticals Inc
06/23/20236:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
06/20/20238:00AMGlobeNewswire Inc.Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)NASDAQ:ARDSAridis Pharmaceuticals Inc
06/15/20235:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
06/15/20235:14PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ARDS